HC Wainwright Cuts Earnings Estimates for scPharmaceuticals

scPharmaceuticals Inc. (NASDAQ:SCPH) – Equities research analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for scPharmaceuticals in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($1.44) per share for the year, down from their prior forecast of ($1.43). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for scPharmaceuticals’ current full-year earnings is ($1.53) per share. HC Wainwright also issued estimates for scPharmaceuticals’ Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.88) EPS and FY2026 earnings at ($0.36) EPS.

Separately, Craig Hallum lowered their target price on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, November 14th.

scPharmaceuticals Price Performance

NASDAQ:SCPH opened at $3.12 on Thursday. The business’s 50-day moving average price is $3.39 and its 200 day moving average price is $3.95. The firm has a market cap of $156.12 million, a P/E ratio of -1.64 and a beta of 0.11. scPharmaceuticals has a 52-week low of $3.07 and a 52-week high of $6.20. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66.

Hedge Funds Weigh In On scPharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. ProShare Advisors LLC acquired a new position in shares of scPharmaceuticals in the 4th quarter valued at $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of scPharmaceuticals by 36.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,973 shares of the company’s stock valued at $78,000 after purchasing an additional 5,827 shares during the period. Deutsche Bank AG boosted its position in shares of scPharmaceuticals by 514.5% in the 4th quarter. Deutsche Bank AG now owns 82,488 shares of the company’s stock valued at $292,000 after purchasing an additional 69,064 shares during the period. Captrust Financial Advisors boosted its position in shares of scPharmaceuticals by 116.1% in the 4th quarter. Captrust Financial Advisors now owns 40,062 shares of the company’s stock valued at $142,000 after purchasing an additional 21,523 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of scPharmaceuticals by 9.0% in the 4th quarter. Bank of America Corp DE now owns 44,037 shares of the company’s stock valued at $156,000 after purchasing an additional 3,647 shares during the period. Institutional investors and hedge funds own 89.52% of the company’s stock.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.